Kori Elkins, MD
Retina Specialist · Portsmouth, VANPI 1265691141
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,356 of the $8,917 with a category attached, or 71.3%. 19 manufacturers reported payments, led by AbbVie at 38.1% of the total. Reporting peaked in 2023 at $3,864 and has fallen 95.4% since, to $178 in 2025.
Across 123 payments — averaging $72.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Bausch & Lomb Americas Inc.$2K
- Cardinal Health 108 LLC$2K
- Genentech USA, Inc.$293
- Regeneron Healthcare Solutions, Inc.$258
- Apellis Pharmaceuticals, Inc.$248
- plus $793 from 13 others
What the payments were for
- Consulting fees$6,35671%
- Food & beverage$2,50328%
- Education$581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $3,398 |
| Bausch & Lomb Americas Inc. | 14 | $2,352 |
| Cardinal Health 108 LLC | 1 | $1,575 |
| Genentech USA, Inc. | 11 | $293 |
| Regeneron Healthcare Solutions, Inc. | 9 | $258 |
| Apellis Pharmaceuticals, Inc. | 10 | $248 |
| Alimera Sciences, Inc. | 8 | $217 |
| Eyepoint US, Inc. | 2 | $149 |
| Sun Pharmaceutical Industries Inc. | 5 | $95 |
| Astellas Pharma US Inc | 3 | $89 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $44 |
| Novartis | 2 | $40 |
| Mallinckrodt Enterprises LLC | 2 | $39 |
| Oyster Point Pharma, Inc. | 1 | $28 |
| Amgen | 1 | $22 |
| Biogen | 1 | $21 |
| Astellas Pharma Global Development | 1 | $19 |
| Shire North American Group Inc | 1 | $15 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,917 in reported general payments places this provider in the 80th percentile of 41 retina specialist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 103 | $4,072 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,645 |
| Ketorolac Tromethamine | 69 | $1,480 |
| Brimonidine Tartrate | 23 | $1,190 |
| Latanoprost | 21 | $343 |
| Timolol Maleate | 16 | $234 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Portsmouth
- Jordana FeinManassas$412K
- Joaquin TosiVirginia Beach$48K
- Mohit NandaCharlottesville$31K
- Muge KesenMc Lean$30K
- Anna MackinRoanoke$26K
- Jon AdlebergChesapeake$21K
- Dal ChunVienna$12K
- Jiwei ShengFairfax$8K
- Timothy ByrnesRoanoke$7K
- Alexander MelamudFairfax$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.